ArticleJournal of pharmaceutical innovation2026
Chewable Tablets for Precise Unit Dosing of Animals.
Article in Journal of pharmaceutical innovation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Regular exposure to low dose of diarrheic shellfish toxins: Implications for the seafood consumer.Current research in food science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Introduction: Peroral administration of preclinical drugs is commonly achieved through oral gavage or food formulations. However, oral gavage induces distress and is unsuitable for behavior studies, whereas food mixing and delivery are less precise. Therefore, we manufactured and tested tablets with the appropriate physical properties for precise unit dosing of laboratory mice. Methods: Various tablet compositions were evaluated for compactability and compressibility and tested for voluntary consumption by CD-1 mice. The most bitter compound known, denatonium benzoate, was added to tablets at escalating doses, and daily consumption by male and female CD-1 mice was measured across four weeks. Results: Tablet consumption increased with the number of exposures in 5 of 6 mice, suggesting that a habituation period was necessary. A bitterant was then added at escalating doses (3 to 48 micrograms) for four weeks. After one week of habituation to placebo tablets, 9 of 11 mice ate all bitter tablets, consuming 97% of tablet masses within the first hour. No changes in bodyweight were noted. Conclusion: These findings support the utility of tablets as a method for drug delivery in laboratory and possibly other settings. Supplementary Information: The online version contains supplementary material available at 10.1007/s12247-025-10312-0.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.